Access to Medicine

Management Approach：

Bora follows the Access to Medicine Index guidelines to build the group policy and implementation strategies commits to do our best to keep products available at affordable prices and ensure patients receive medicines they need.

Promise of Support™ Program

Our subsidiary, Upsher-Smith, launches the Promise of Support™ Program for our rare disease portfolio. The rare disease prescription drug brands under this program will offer services and support that meet the Promise of Support™ standard. In 2023, we donated medications valued at $162,858, and by 2024, our donations grew further to $165,332, demonstrating our ongoing commitment and dedication to social responsibility.

A rare disease often creates significant financial, emotional, physical and psychological challenges for patients and their families. Accessing critical prescription drugs for rare disease patients can add to the already significant burden.. For the branded prescription drugs we provide for rare disease, Upsher-Smith is committed to continuously learning about the unique challenges associated with each disease state and each therapy. We will do our best to provide value-added services and support to reduce friction in the drug therapy journey.

Currently, this program covers three products, including Vigadrone® powder for oral solution, Vigadrone® tablets, and TORPENZ™ tablets.

Drug Donation Project

Bora Pharmaceuticals, guided by the mission “Contributing to Better Health All Over the World,” fully recognizes Bora corporate social responsibility. The company actively engages in social justice initiatives, placing particular emphasis on meeting the healthcare needs of underserved communities.

To ensure everyone has access to equitable healthcare, Bora Pharmaceuticals has long implemented various donation programs, proactively providing necessary medicines to populations with limited economic or geographical resources. Upsher-Smith, a subsidiary of Bora Pharmaceuticals, donated medications valued at USD $162,858 and USD$ 165,332 in 2023and 2024, respectively.

Responsible Pricing

Bora Pharmaceuticals upholds the principles of fairness and affordability by adopting a tiered pricing strategy based on the World Health Organization’s Guidelines for National Drug Pricing Policies. The company conducts market analysis across different countries, considering factors such as GDP and income levels to set prices. This approach ensures that drug prices are reasonable and aligned with local economic conditions, thereby enhancing patient affordability and access to medications.